Perseus Proteomics, Inc. (JP:4882) has released an update.
Perseus Proteomics Inc. and UBE Corporation have joined forces in a new research agreement to develop antibody-drug conjugates (ADCs), focusing on the promising candidate PPMX-T004 and other exploratory ADC research. While the immediate financial impact is minimal, both companies anticipate significant long-term business growth from this collaboration.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.